Last Price$239.35Cboe Real-Time Last Sale as of 9:56AM ET 6/26/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.94(0.39%)
Bid (Size)$239.09 (24)
Ask (Size)$239.42 (100)
Day Low / High$240.65 - 242.68
Volume80.8 K

View Biotechnology IndustryPeer Comparison as of 06/26/2019


Biogen Inc ( NASDAQ )

Price: $239.35
Change: -0.94 (0.39%)
Volume: 80.8 K
9:56AM ET 6/26/2019

Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $178.78
Change: -1.37 (0.76%)
Volume: 30.6 K
9:55AM ET 6/26/2019

Illumina Inc ( NASDAQ )

Price: $355.18
Change: -2.90 (0.81%)
Volume: 27.7 K
9:57AM ET 6/26/2019

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $311.51
Change: -1.39 (0.44%)
Volume: 34.4 K
9:54AM ET 6/26/2019

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $124.30
Change: -0.85 (0.68%)
Volume: 54.6 K
9:56AM ET 6/26/2019

Read more news Recent News

S&P 500 Movers: Allergan Surges 27%, Leads Gainers; AbbVie Sinks 15%
12:07PM ET 6/25/2019 MT Newswires

S&P 500 Top % Movers as of 12:04 pm ET Gainers AGN, +26.6% NKTR, +4.3% MYL, +3.5% BIIB, +3% MOS, +3% Losers ABBV, -14.9% LEN, -5.4% HRL, -3.5% ...

Analyst Actions: Standpoint Research Upgrades Biogen to Buy From Hold
11:06AM ET 6/05/2019 MT Newswires

Biogen's (BIIB) average rating among analysts is a hold, with an average price target of $283. Price: 225.82, Change: -1.18, Percent Change: -0.52 ...

Insider Trends: Insider at Biogen Acquires Stock Via Conversion of Option/Derivative Security Sells Portion to Pay Tax, Buy Trend Intact
4:59PM ET 6/04/2019 MT Newswires

On Jun 01, 2019, Michael D Ehlers, EVP, Research and Development, exercised options/derivative securities for 1,126 shares of Biogen (BIIB) and sold 960...

Biogen Reports Positive Interim Data from Study of Diroximel Fumarate to Treat Multiple Sclerosis
7:45AM ET 5/30/2019 MT Newswires

Biogen (BIIB) said data from a study has indicated its investigational treatment diroximel fumarate was generally well tolerated in people with relapsing...

View all Commentary and Analysis

5 ROE Stocks to Buy as Trade Talks Resume Ahead of G20 Summit
8:07AM ET 6/25/2019 Zacks

ROE is often used to compare the profitability of a company with other firms in the industry - the...

3 Reasons Why Growth Investors Shouldn't Overlook Biogen (BIIB)
7:45AM ET 6/25/2019 Zacks

Biogen (BIIB) is well positioned to outperform the market, as it exhibits above-average growth in...

The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon
7:40AM ET 6/25/2019 Zacks

The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon

Top Stock Reports for Union Pacific, NextEra & Biogen
2:37PM ET 6/24/2019 Zacks

Top Stock Reports for Union Pacific, NextEra & Biogen

Company Profile

Business DescriptionBiogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. View company web site for more details
Address225 Binney Street
Cambridge, Massachusetts 02142
Number of Employees7,800
Recent SEC Filing06/20/20198-K
Chief Executive Officer & DirectorMichel Vounatsos
Chief Financial Officer & Executive Vice PresidentJeffrey D. Capello
Chief Medical Officer & Executive Vice PresidentAlfred W. Sandrock
Chief Information Officer & Senior Vice PresidentMark Hernon

Company Highlights

Price Open$241.45
Previous Close$240.29
52 Week Range$216.12 - 388.67
Market Capitalization$46.4 B
Shares Outstanding193.9 M
SectorHealth Technology
Next Earnings Announcement07/23/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings10.35
Earnings per Share$24.89
Beta vs. S&P 500N/A
Revenue$12.1 B
Net Profit Margin37.88%
Return on Equity35.29%

Analyst Ratings as of 06/14/2019

Consensus RecommendationConsensus Icon
Powered by Factset